David Simmons, PhD, MBA is Chief Scientific Officer at Cellzome. After a successful academic career at several leading research institutions, including the University of Oxford, David joined SmithKline Beecham and later also Celltech, where he was Director of Research, responsible for the NCE drug discovery pipeline. In his last position, before joining Cellzome, David was Vice President, Inflammation Discovery Research at Wyeth Research in Boston, and co-chair of the Inflammation Therapeutic Area Leadership team. In this function, David was responsible for the delivery of innovative pipeline projects and clinical development candidate drugs for inflammatory diseases. David is currently a grant panel reviewer for the UK's Multiple Sclerosis Society and is a reviewer for the Wellcome Trust, Medical Research Council, Leukaemia Research Fund, Cancer Research Campaign and Arthritis Research Campaign.

Professor Ruedi Aebersold obtained his Ph.D. in Cellular Biology at the Biocenter of the University of Basel before he became a faculty member at the University of British Columbia and then at the University of Washington in Seattle. There he co-founded the Institute for Systems Biology in 2000. Since 2004 he is a professor at the Swiss Federal Institute of Technology (ETH Zurich) and the University of Zurich. Prof. Aebersold is a pioneer in the field of proteomics. He developed a series of methods that have found wide application in this field, including methods to enable reliable protein quantification by mass spectrometry. He serves on Scientific Advisory Committees of several academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics. He is the recipient of numerous awards for his contribution to the field of protein sciences and proteomics including the ASBMB Herbert Sober award (2009) the Otto Naegeli Prize (2009), the ABRF Award (2008), the FEBS Buchner Medal (2006), the HUPO Award (2005), the ASMS Biemann medal (2002) the Widmer award (2002), and the 2003 World Technology award. He has published more than 500 peer reviewed papers.

Professor Christopher D. Buckley is arc Professor of Rheumatology at the MRC Centre for Immune Regulation at the University of Birmingham, UK. He qualified in 1990 and was appointed as arc Professor and Honorary Consultant in Rheumatology in 2002. Specialist interests include mechanisms involved in the persistence of inflammation and early inflammatory arthritis. He read biochemistry at University of Oxford (1985) and trained as a doctor at the Royal Free Hospital, London (1990). He achieved Membership of the Royal College of Physicians (MRCP) in 1993 during subsequent training in General Medicine at Hammersmith Hospital, London and John Radcliffe Hospital, Oxford. DPhil (1996) arising from Wellcome Training Fellowship with Professor J. Bell and Dr. D. Simmons at the Institute of Molecular Medicine, Oxford. He undertook rheumatology training with Dr. A. Mowatt and Dr. P. Wordsworth at the Nuffield Orthopaedic Hospital, Oxford. In 1996, he attained a Wellcome Clinician Scientist Fellowship and joined the Department of Rheumatology at the University of Birmingham. In 2000, he became a Senior Lecturer and from 2001 to 2006 was MRC Senior Clinical Fellow, at the MRC Center for Immune regulation.

Professor Sir Philip Cohen received his BSc and PhD (1969) at University College London and then spent two years as a postdoc with Edmond Fischer at the University of Washington, Seattle, USA. In 1971 he returned to the UK to become a Faculty member of the University of Dundee, Scotland where he has worked ever since. He has been a Royal Society Research Professor since 1984, Director of the Medical Research Council Protein Phosphorylation Unit since 1990, and became the President of the British Biochemical Society in 2006. For the past thirty-eight years, Prof. Cohen's major research interest has been to understand the role of protein phosphorylation in cell regulation and human disease. Over this period he has made important contributions to our understanding of the control of glycogen metabolism, the structure and regulation of protein phosphatases, MAP kinase cascades and insulin signal transduction. Professor Cohen has received numerous awards for his research contributions, was elected a Fellow of both The Royal Society of London and The Royal Society of Edinburgh in 1984 and was knighted by the Queen in 1998. Most recently Sir Philip was awarded with the UK Royal Society Medal and elected as a fellow to the US National Academy of Sciences.

Professor Anne Ferguson Smith has established an international reputation for her work integrating the epigenetic control of genome function with developmental and physiological processes relevant to health and disease. She has more than two decades of experience in the exploration of links between gene regulation, large and small non-coding RNAs and epigenetic modifications, and the consequences of perturbations in these interactions for pre and postnatal well-being. She is Professor of Developmental Genetics at the University of Cambridge and contributes to a range of national and international review panels and initiatives at the interface of genomic and epigenomics research.

Professor Tony Kouzarides is an internationally recognized leader in the field of epigenetics and his research has led to fundamental insights into the function of chromatin modifications and their role in disease. Prof. Kouzarides is a Royal Society Professor at the University of Cambridge and Deputy Director of Gurdon Institute. He did his PhD at the University of Cambridge and after two postdoctoral fellowships at the MRC Laboratory of Molecular Biology in Cambridge and the New York University Medical Center, he started his independent research group and has been at the Gurdon Institute since 1991. Prof. Kouzarides is a member of the Science Strategy Advisory Group for Cancer Research UK and SAB member of several research institutes in Greece and Spain. Prof. Kouzarides is a member of the European Molecular Biology organization, the British Academy of Medical Sciences and has additionally been awarded several prestigious international prizes for his research. He is the author of more than 130 publications in research journals. Prof. Kouzarides is also the founder and director of "Vencer el Cancer" (Conquer Cancer), a charity based in Spain which raises public funds for cancer research and anti-cancer drug discovery.

Professor Jeannie Lee is an Investigator of the Howard Hughes Medical Institute and Professor of Genetics (and Pathology) at Harvard Medical School and the Massachusetts General Hospital. She was an undergraduate at Harvard University where she majored in Biochemistry and Molecular Biology, and worked with Nancy Kleckner on the control of Tn10 transposition by antisense RNA. She then obtained M.D. Ph.D degrees from the University of Pennsylvania School of Medicine, where she became interested in epigenetic regulation of human disease while a dissertation student with Robert L. Nussbaum. Afterwards, she trained briefly in Clinical Pathology at the Massachusetts General Hospital, before joining Rudolf Jaenisch at the Whitehead Institute as a postdoctoral fellow. Since she became independent in 1997, her lab's interests have included X-inactivation, imprinting, the emerging link between noncoding RNA and chromatin control, and the evolutionary history of sex chromosomes and dosage compensation. She has received the Basil O'Connor Scholar Award from the March of Dimes and the Pew Scholars Award from the Pew Foundation. Dr. Lee is also the recipient of the 2010 Molecular Biology Prize from the National Academy of Sciences, U.S.A, is a Fellow of the AAAS, and currently serves on the Board of Directors for the Genetics Society of America.

Dr Peter Machin has more than thirty years experience of drug discovery and development in major pharmaceutical companies. He has held a number of senior positions; at Roche as head of chemistry in the UK, then at SmithKline Beecham as Vice President of Discovery Chemistry Europe and most recently, as Global Senior Vice President of Discovery Research Chemistry at GlaxoSmithKline. He has broad experience of lead discovery and optimisation through to development and has been responsible for the identification of a significant number of clinical candidates, across a wide range of therapeutic indications, two of which have reached market. Peter Machin gained his PhD in organic chemistry from Imperial College, London. He is a Fellow of the Academy of Medical Sciences and is Honorary Treasurer of the Royal Society of Chemistry.

Professor Diane Mathis is a Professor of Pathology at Harvard Medical School, a Principal Faculty member of the Harvard Stem Cell Institute and an Associate Member at the Broad Institute. Her laboratory works in the fields of T-cell differentiation and autoimmunity, with a special emphasis on exploiting the most advanced transgenic and gene-targeting technologies. Prof. Diane Mathis obtained a BSc from Wake Forest University and a Ph.D. from the University of Rochester. She performed postdoctoral studies at the Laboratoire de Génétique Moléculaire des Eucaryotes in Strasbourg, France and at Stanford University Medical Center. Prof. Mathis returned to France at the end of 1983, where she established a laboratory at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg. The lab moved to the Joslin Diabetes Center at the end of 1999 and joined the Harvard Medical School Pathology department in spring 2009. Prof. Mathis was elected to the National Academy of Sciences in 2003 and to the Leopoldia (the German Academy of Sciences) in 2007. She received numerous awards for her work and serves on the editorial boards of many prestigious scientific journals, including Science and Cell. She has published more than 200 peer reviewed scientific papers.

Professor David Sabatini is Principle Investigator and Member of the Whitehead Institute, Associate Professor of Biology of MIT, Senior Associate Member of the Broad Institute and Member of the Cancer Center of MIT. He read Biology at Brown University and studied medicine and a PhD at Johns Hopkins University School of Medicine. He is an associate professor of biology at MIT, an associate member at the MIT Center for Cancer Research and an associate member at the Broad Institute. Prof. Sabatini studies the mechanisms that regulate cell growth. Spurred by the discovery of a cellular pathway that helps switch cell growth on and off, research in the Sabatini lab has linked growth to a cell's ability to sense nutrients in its environment This growth-triggering system, known as the TOR pathway, is composed of a complex of proteins that respond to nutrient cues. Sabatini is working to identify TOR pathway components and study how they interact and work. His efforts to understand mammalian TOR at the cellular level have provided a new way to investigate the role nutrients and metabolism play in disease.

Professor Giulio Superti-Furga is scientific Director and CEO of the Research Center of Molecular Medicine of the Austrian Academy of Sciences and Medical University of Vienna. Prof. Superti Furga performed his undergraduate and graduate studies in molecular biology at the University of Zurich, at Genentech Inc. and at the Institute for Molecular Pathology in Vienna (I.M.P.). He was a post-doctoral fellow and Team Leader at the European Molecular Biology Laboratory (EMBL) until 2004. For several years he served as professor of Biotechnology at the University of Bologna. In 2000, he co-founded Cellzome, where he was a Scientific Director and responsible for the Heidelberg research site. His most significant scientific contributions are the elucidation of basic regulatory mechanisms of tyrosine kinases in human cancers and the discovery of fundamental organization principles of the proteome of higher organisms.